Neurotech scores another win in pre-clinical studies for its proprietary MS cannabis treatment, shares climb
Health & Biotech
Health & Biotech
Link copied to
Results demonstrated the ability of Neurotech’s NTI/Dolce strains to suppress COX-2 – the main enzyme that causes inflammation in multiple sclerosis patients.
Clinical-stage medicinal cannabis company Neurotech International (ASX:NTI) continues to make headway in the development of its proprietary drug formulation targeting multiple sclerosis (MS).
NTI provided another update for investors this morning on the extensive pre-clinical trial program for its NTI/Dolce cannabis strains.
Previous studies showed that when applied to two key MS neuro-markers – GM-CSF and TNF Alpha – the NTI/Dolce Strains showed a material suppression of 40% and 30% respectively, compared to CBD alone which had no significant effect
In its latest study, Neurotech found more success in the application of the NTI/Dolce cannabis strains in the treatment of Cyclooxygenase-2 (COX-2) — considered the main enzyme responsible for causing inflammation due to MS.
The pre-clinical trials demonstrated the ability of the NTI/Dolce strains to “suppress or inhibit” the occurrence of COX-2 in human derived microglial cells, the company said.
And when compared to CBD alone, NTI/Dolce strains were “up to three times more powerful in supressing COX-2, both pre and post inflammatory insult”.
“These results re-confirm the potent anti-inflammatory properties of NTI/Dolce strains and provide further evidence for their development as neuro anti-inflammatory therapies across a number of neuro diseases,” said NTI chairman Brian Leedman.
For NTI, the next stage of its pre-clinical trial program will centre around the comparison of NTI/Dolce strains against current pharmaceutical treatment options, which have multiple side-effect implications.
Investors can expect an update on the results of those studies before the end of this month, with the initiation of Phase II trials scheduled for the March quarter of 2022.
In addition, Phase I/II clinical studies for NTI’s treatment solution for autistic children remain ongoing, and are now approaching the half way point.
So along with the positive developments for its proprietary MS treatment, the company is “looking forward to delivering an exciting second half in this calendar year”, Leedman said.
This article was developed in collaboration with Neurotech International, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.